Bisphosphonates in the treatment of thalassemia-induced osteoporosis

Osteoporosis International

Volumn 13, Issue 8, 2002, Pages 644-649

  Morabito, N ^a   Lasco, A ^a   Gaudio, A ^a   Crisafulli, A ^a   Di Pietro, C ^a   Meo, A ^a   Frisina, N ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Alendronate; BMD; Clodronate; Thalassemia

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; COLECALCIFEROL; DEFEROXAMINE; EPIESTROL; ESTRADIOL; IRON CHELATING AGENT; MEDROXYPROGESTERONE ACETATE; METHYLTESTOSTERONE;

ABDOMINAL PAIN; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE DENSITY; BONE DISEASE; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; INJECTION SITE; IRON OVERLOAD; MALE; OSTEOLYSIS; OSTEOPOROSIS; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THALASSEMIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALENDRONATE; ANALYSIS OF VARIANCE; BETA-THALASSEMIA; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CLODRONIC ACID; DENSITOMETRY, X-RAY; DIPHOSPHONATES; FEMALE; HUMANS; MALE; OSTEOPOROSIS; PLACEBO EFFECT;

EID: 0036342860     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980200087     Document Type: Article

References (38)

1. Multicentre study on prevalence of fractures in transfusion-dependent thalassaemic patients
2. Abnormal bone metabolism in thalassemia
3. High incidence of osteoporosis in thalassaemia major
4. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: New therapeutic approaches
5. Estrogen deficiency in adolescents and young adults: Impact on bone mineral content and effects of estrogen replacement therapy
6. Effect of testosterone on bone density and bone metabolism in adolescent male hypogonadism
7. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
8. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
9. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone
10. New bisphosphonates in osteoporosis
11. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
12. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
13. Alendronate for the treatment of osteoporosis in men
14. Clodronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease
15. Clodronate and osteoporosis
16. Intramuscular clodronate therapy in postmenopausal osteoporosis
17. Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass
18. Effects of clodronate on vertebral fracture risk in osteoporosis: A 1-year interim analysis
19. Bone disease in beta-thalassaemia major
20. Effects of hormonal replacement therapy on bone metabolism in young adults with β-thalassemia major
21. Bone resorption is increased in young adults with thalassaemia major
22. Effects of iron overload on bone remodelling in pigs
23. Calcium phosphate metabolism and bone disease in patients with homozygous thalassemia
24. Thalassemic osteoarthropathy
25. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine
26. Bone mineral density in prepubertal children with beta-thalassemia: Correlation with growth and hormonal data
27. Osteoporosis and β-thalassemia major: Role of the IGF-1/IGFBP3 axis
28. Oxygen tension regulates osteoblast function
29. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major
30. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
31. Determinants of bone loss from the femoral neck in women of different ages
32. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo
33. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
34. Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure
35. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
36. Bone density and metabolism in thalassaemia
37. Effect of intramuscular clodronate on bone mass and metabolism in osteoporotic women